Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.

about

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK.

Item

http://www.wikidata.org/entity/Q54962623

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@en

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@nl

type

Item

label

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@en

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@nl

prefLabel

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@en

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@nl

P1476

Cost-effectiveness of solifena ...... overactive bladder in the UK.

@en

P2093

Colette Mankowski

http://www.w3.org/2001/XMLSchema#string

Con Kelleher

http://www.w3.org/2001/XMLSchema#string

Isaac Odeyemi

http://www.w3.org/2001/XMLSchema#string

Jameel Nazir

http://www.w3.org/2001/XMLSchema#string

Khaled Maman

http://www.w3.org/2001/XMLSchema#string

Samuel Aballéa

http://www.w3.org/2001/XMLSchema#string

Zalmai Hakimi

http://www.w3.org/2001/XMLSchema#string

P2860

Which anticholinergic drug for overactive bladder symptoms in adults

Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Cost effectiveness of mirabegron compared with tolterodine extended release for the treatment of adults with overactive bladder in the United Kingdom

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder.

Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons.

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.

Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.

Solifenacin for overactive bladder: a systematic review and meta-analysis.

Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.

P304

1438721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/20016689.2018.1438721

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29686801

http://www.w3.org/2001/XMLSchema#string

P932

5907635

http://www.w3.org/2001/XMLSchema#string